
This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of
the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

* WELCOME TO THE *
* U.S. PATENT TEXT FILE *

=> s biodeg? and (matrix or network) and (antibod? or immunoglo?)

11270 BIODEG?

137484 MATRIX

127056 NETWORK

25104 ANTIBOD?

7720 IMMUNOGLO?

L1 488 BIODEG? AND (MATRIX OR NETWORK) AND (ANTIBOD? OR IMMUNOGLO?)
)

=> s l1 and fibrin

3272 FIBRIN

L2 87 L1 AND FIBRIN

=> d 1-87

1. 5,676,720, Oct. 14, 1997, Method of forming a porous glass substrate;
Paul Ducheyne, et al., 65/17.5, 17.3, 17.6, 22, 23, 31, 33.1, 33.9 [IMAGE
AVAILABLE]

2. 5,670,336, Sep. 23, 1997, Method for recombinant production of
osteogenic protein; Hermann Oppermann, et al., 435/69.1 [IMAGE AVAILABLE]

3. 5,667,778, Sep. 16, 1997, Injectable bladder muscle cells-polymer
suspension for treatment of vesicoureteral reflux and incontinence;
Anthony Atala, 424/93.7, 423; 623/11, 14 [IMAGE AVAILABLE]

4. 5,665,723, Sep. 9, 1997, Fibrinogen receptor antagonists; George D.
Hartman, et al., 514/255, 414; 544/373; 548/454, 466, 467 [IMAGE
AVAILABLE]

5. 5,665,391, Sep. 9, 1997, Cultured, full-thickness integument
substitutes based on three-dimensional **matrix** membranes; Peter Lea,
424/484, 400, 486, 488, DIG.7; 623/15 [IMAGE AVAILABLE]

6. 5,662,904, Sep. 2, 1997, Anti-scarring compositions comprising growth
factor neutralizing **antibodies**; Mark William James Ferguson, et al.,
424/130.1, 145.1; 530/387.1, 388.24, 391.1, 391.7 [IMAGE AVAILABLE]

7. 5,661,127, Aug. 26, 1997, Peptide compositions with growth
factor-like activity; Rajendra S. Bhatnagar, et al., 514/16; 530/329
[IMAGE AVAILABLE]

8. 5,660,692, Aug. 26, 1997, Method of crosslinking amino acid-containing polymers using photoactivatable chemical crosslinkers; Anthony B. Nesburn, et al., 204/157.68; 530/356, 409 [IMAGE AVAILABLE]

9. 5,658,929, Aug. 19, 1997, Sulfonamide fibrinogen receptor antagonists; Mark E. Duggan, et al., 514/317; 546/237 [IMAGE AVAILABLE]

10. 5,658,331, Aug. 19, 1997, Biocompatible perforated membranes, processes for their preparation, their use as a support in the in vitro growth of epithelial cells, the artificial skin obtained in this manner, and its use in skin grafts; Francesco Della Valle, et al., 623/15, 11, 66 [IMAGE AVAILABLE]

11. 5,655,546, Aug. 12, 1997, Method for cartilage repair; Alan A. Halpern, 128/898; 424/423; 623/18 [IMAGE AVAILABLE]

12. 5,652,347, Jul. 29, 1997, Method for making functionalized derivatives of hyaluronic acid; Tara Pouyani, et al., 536/18.5, 123.1, 124, 126 [IMAGE AVAILABLE]

13. 5,650,447, Jul. 22, 1997, Nitric oxide-releasing polymers to treat restenosis and related disorders; Larry K. Keefer, et al., 514/772.4, 611, 772.6, 773, 784, 785, 788 [IMAGE AVAILABLE]

14. 5,650,164, Jul. 22, 1997, Process for preparing artificial skin with biocompatible perforated membranes; Francesco Della Valle, et al., 424/422, 425; 523/113; 623/15 [IMAGE AVAILABLE]

15. 5,648,368, Jul. 15, 1997, Fibrinogen receptor antagonists; Melissa S. Egbertson, et al., 514/331, 327, 329, 330; 546/233, 234 [IMAGE AVAILABLE]

16. 5,648,301, Jul. 15, 1997, Bioactive material template for in vitro synthesis of bone tissue; Paul Ducheyne, et al., 501/39, 55, 63, 70 [IMAGE AVAILABLE]

17. 5,643,789, Jul. 1, 1997, Bioactive material template for in vitro synthesis of bone tissue; Paul Ducheyne, et al., 435/402; 424/422; 435/1.1, 325, 378 [IMAGE AVAILABLE]

18. 5,635,493, Jun. 3, 1997, Methods and compositions for poly-.beta.-1-4-N-acetylglucosamine chemotherapeutics; John N. Vournakis, et al., 514/55, 2, 8, 62; 536/20, 55.2 [IMAGE AVAILABLE]

19. 5,628,983, May 13, 1997, Squid magnetometry using paramagnetic metal chelates; Jo Klaveness, et al., 424/9.364; 128/653.4, 654; 436/173; 514/492, 502, 836 [IMAGE AVAILABLE]

20. 5,627,233, May 6, 1997, Multifunctional organic polymers; Jeffrey A. Hubbell, et al., 525/54.1, 54.2, 54.3; 528/354 [IMAGE AVAILABLE]

21. 5,626,863, May 6, 1997, Photopolymerizable ****biodegradable**** hydrogels as tissue contacting materials and controlled-release carriers; Jeffrey A. Hubbell, et al., 424/426; 128/898; 424/489; 514/772.1, 772.3, 773, 777; 525/54.1, 54.2, 408, 413, 415; 528/354, 361 [IMAGE AVAILABLE]

22. 5,624,679, Apr. 29, 1997, Methods and compositions for poly-.beta.-1-4-N-acetylglucosamine biological barriers; John N. Vournakis, et al., 424/444, 443, 488; 514/55; 536/20, 55.2 [IMAGE AVAILABLE]

23. 5,623,064, Apr. 22, 1997, Poly-.beta.-1.fwdarw.-4-N-acetylglucosamine; John N. Vournakis, et al., 536/20; 424/443, 444, 488, 499; 435/84; 536/55.2 [IMAGE AVAILABLE]

24. 5,618,563, Apr. 8, 1997, ****Biodegradable**** polymer matrices for sustained delivery of local anesthetic agents; Charles B. Berde, et al., 424/501, 499; 514/818 [IMAGE AVAILABLE]

25. 5,616,568, Apr. 1, 1997, Functionalized derivatives of hyaluronic acid; Tara Pouyani, et al., 514/54, 53; 536/17.2, 18.7, 55, 55.1, 55.3, 123.1 [IMAGE AVAILABLE]

26. 5,612,028, Mar. 18, 1997, Method of regenerating or replacing cartilage tissue using amniotic cells; Jonathan M. Sackier, et al., 424/93.7, 582; 623/18, 19, 20, 21 [IMAGE AVAILABLE]

27. 5,609,629, Mar. 11, 1997, Coated implantable medical device; Neal E. Fearnot, et al., 623/1; 604/53, 265; 623/11, 12 [IMAGE AVAILABLE]

28. 5,599,558, Feb. 4, 1997, Selecting amounts of platelet releasate for efficacious treatment of tissue; Richard H. Gordinier, et al., 424/532, 520, 529; 436/503; 514/2, 21, 773, 802, 886, 887; 530/351, 380, 381, 382, 383, 384, 399, 829, 830 [IMAGE AVAILABLE]

29. 5,597,578, Jan. 28, 1997, TGF-.beta. protein compositions for inhibition of cell proliferation; Dennis M. Brown, et al., 424/422, 423, 426, 484; 514/12, 21; 530/350, 356, 399 [IMAGE AVAILABLE]

30. 5,585,116, Dec. 17, 1996, Method of manufacture of a material for osteoplasty from a natural bone tissue and material obtained thereby; Robert Boniface, et al., 424/549, 422; 435/378; 514/588; 623/16 [IMAGE AVAILABLE]

31. 5,580,569, Dec. 3, 1996, Article for tissue-specific delivery of therapeutic agents; Vincent C. Giampapa, 424/426; 514/772.6, 774, 953; 604/57; 606/46 [IMAGE AVAILABLE]

32. 5,575,815, Nov. 19, 1996, Local polymeric gel therapy; Marvin Slepian, et al., 623/1; 604/890.1, 891.1; 623/11 [IMAGE AVAILABLE]

33. 5,567,440, Oct. 22, 1996, Methods for modifying cell contact with a surface; Jeffrey A. Hubbell, et al., 424/484, 485, 486, 488 [IMAGE AVAILABLE]

34. 5,567,435, Oct. 22, 1996, Photopolymerizable ****biodegradable**** hydrogels as tissue contacting materials and controlled-release carriers; Jeffrey A. Hubbell, et al., 424/426; 128/898; 424/489, 490; 514/772.1, 772.3, 773, 777; 525/54.1, 54.2, 408, 413, 415; 528/354, 361 [IMAGE AVAILABLE]

35. 5,565,210, Oct. 15, 1996, Bioabsorbable wound implant materials; Arthur L. Rosenthal, et al., 424/426, 423, 425; 514/773, 774, 777, 781, 953 [IMAGE AVAILABLE]

36. 5,563,158, Oct. 8, 1996, Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists; William F. DeGrado, et al., 514/340, 374, 376, 378, 380; 546/271.4, 272.1; 548/215, 225, 235, 240, 243, 248 [IMAGE AVAILABLE]

37. 5,534,269, Jul. 9, 1996, Method of producing sustained-release preparation; Yasutaka Igari, et al., 424/489, 85.4, 484; 514/2, 21, 964 [IMAGE AVAILABLE]

38. 5,530,102, Jun. 25, 1996, Methods and compositions for the direct concentrated delivery of passive immunity; Anthony G. Gristina, et al., 530/391.1, 388.4; 604/46, 93; 606/76 [IMAGE AVAILABLE]

39. 5,525,617, Jun. 11, 1996, Fibrinogen receptor antagonists; George D. Hartman, et al., 514/319, 428; 546/205; 548/567 [IMAGE AVAILABLE]

40. 5,523,302, Jun. 4, 1996, Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists; Gary A. Cain, et al., 514/252, 85, 255, 317, 533, 539, 562, 567, 631, 634; 544/337, 374, 389, 394, 395, 399; 546/239; 548/240, 243, 244, 245 [IMAGE AVAILABLE]

41. 5,510,102, Apr. 23, 1996, Plasma and polymer containing surgical hemostatic adhesives; Kent C. Cochrum, 424/78.08; 128/DIG.22; 424/530; 602/52 [IMAGE AVAILABLE]

42. 5,505,945, Apr. 9, 1996, Method and compositions for the direct concentrated delivery of passive immunity; Anthony G. Gristina, et al., 424/164.1, 130.1, 150.1, 163.1, 165.1, 169.1, 170.1; 530/387.1, 388.1, 388.2, 388.4, 389.1, 389.5 [IMAGE AVAILABLE]

43. 5,496,552, Mar. 5, 1996, Osteogenic devices; Thangavel Kuberasampath, et al., 424/420, 422, 423, 424 [IMAGE AVAILABLE]

44. 5,496,534, Mar. 5, 1996, Squid magnetometry using ferri-and

ferromagnetic particles; Jo Klaveness, et al., 424/9.32, 9.322, 646, 648;
436/173 [IMAGE AVAILABLE]

45. 5,494,921, Feb. 27, 1996, Fibrinogen receptor antagonists; Melissa
S. Egbertson, et al., 514/331, 428; 546/233; 548/572 [IMAGE AVAILABLE]

46. 5,482,925, Jan. 9, 1996, Complexes of nitric oxide with
cardiovascular amines as dual acting cardiovascular agents; Thomas C.
Hutsell, 514/11, 2, 21, 56, 565; 530/300, 311, 316, 350, 855; 536/21;
562/560 [IMAGE AVAILABLE]

47. 5,478,739, Dec. 26, 1995, Three-dimensional stromal cell and tissue
culture system; Sandra R. Slivka, et al., 435/399; 623/15 [IMAGE
AVAILABLE]

48. 5,468,845, Nov. 21, 1995, ****Antibodies**** to osteogenic proteins;
Hermann Oppermann, et al., 530/387.9, 350 [IMAGE AVAILABLE]

49. 5,466,462, Nov. 14, 1995, Heteromorphic sponges containing active
agents; Arthur L. Rosenthal, et al., 424/426, 423; 514/773, 774, 777,
781; 604/359, 360, 364, 368, 369, 379 [IMAGE AVAILABLE]

50. 5,464,013, Nov. 7, 1995, Medical scanning and treatment system and
method; Jerome H. Lemelson, 128/653.1, 659; 378/62, 65, 68; 604/50;
606/10, 11 [IMAGE AVAILABLE]

51. 5,462,990, Oct. 31, 1995, Multifunctional organic polymers; Jeffrey
A. Hubbell, et al., 525/54.1, 54.2, 54.3; 528/354 [IMAGE AVAILABLE]

52. 5,456,663, Oct. 10, 1995, Drugs and methods for treating diseases;
Jerome H. Lemelson, 604/50; 424/450; 604/890.1, 891.1 [IMAGE AVAILABLE]

53. 5,451,578, Sep. 19, 1995, Fibrinogen receptor antagonists; David A.
Claremon, et al., 514/212, 19, 278; 530/323; 540/543, 597; 546/16 [IMAGE
AVAILABLE]

54. 5,428,014, Jun. 27, 1995, Transglutaminase cross-linkable
polypeptides and methods relating thereto; Virender Labroo, et al.,
514/12, 13, 14, 15, 16; 530/324, 326, 327, 328, 329, 345, 350 [IMAGE
AVAILABLE]

55. 5,410,016, Apr. 25, 1995, Photopolymerizable ****biodegradable****
hydrogels as tissue contacting materials and controlled-release carriers;
Jeffrey A. Hubbell, et al., 528/354; 128/898; 424/426, 489; 514/772.1,
772.3, 773, 777; 522/14, 26, 44, 48, 88, 181; 525/54.1, 54.2, 408, 413,
415; 528/361 [IMAGE AVAILABLE]

56. 5,397,791, Mar. 14, 1995, Fibrinogen receptor antagonists; George D.
Hartman, et al., 514/318, 183, 210, 233.8, 235.2, 255, 256, 314, 321,
323, 331, 338; 540/200, 480; 544/111, 133, 145, 148, 335, 368; 546/167,

193, 197, 201, 235, 281.1, 291, 293; 548/204, 307.1, 311.7; 549/32 [IMAGE AVAILABLE]

57. 5,384,109, Jan. 24, 1995, Diagnostic magnetometry using superparamagnetic particles; Jo Klaveness, et al., 424/9.3; 128/653.1, 653.4; 324/248; 423/632, 633; 424/9.32, 9.322, 9.34, 9.35, 9.363, 9.364; 436/173; 514/54, 60 [IMAGE AVAILABLE]

58. 5,358,956, Oct. 25, 1994, Fibrinogen receptor antagonists; George D. Hartman, et al., 514/331, 305, 323, 326, 538; 546/133, 201, 208, 210, 232, 233, 234; 562/430, 439, 440, 442, 451 [IMAGE AVAILABLE]

59. 5,354,557, Oct. 11, 1994, Osteogenic devices; Hermann Oppermann, et al., 424/423, 422, 424, 426 [IMAGE AVAILABLE]

60. 5,352,448, Oct. 4, 1994, Oral administration of antigens; Terry L. Bowersock, et al., 424/438, 234.1, 255.1, 280.1, 426, 434, 435, 486, 487, 823 [IMAGE AVAILABLE]

61. 5,340,798, Aug. 23, 1994, Fibrinogen receptor antagonists; Ruth F. Nutt, et al., 514/18, 19; 530/330, 331 [IMAGE AVAILABLE]

62. 5,334,596, Aug. 2, 1994, Fibrinogen receptor antagonists; George D. Hartman, et al., 514/301, 302; 546/114, 116 [IMAGE AVAILABLE]

63. 5,328,997, Jul. 12, 1994, Processes for making proteins having anticoagulant properties; George P. Vlasuk, et al., 536/23.5; 435/69.1, 252.3, 320.1; 530/324, 334 [IMAGE AVAILABLE]

64. 5,326,356, Jul. 5, 1994, Biocompatible perforated membranes, processes for their preparation, their use as a support in the in vitro growth of epithelial cells, the artificial skin obtained in this manner, and its use in skin grafts; Francesco Della Valle, et al., 623/15; 424/422, 425; 428/131; 623/11, 66 [IMAGE AVAILABLE]

65. 5,324,819, Jun. 28, 1994, Osteogenic proteins; Hermann Oppermann, et al., 530/350; 435/69.1, 172.3, 235.1, 252.3, 320.1; 530/395, 840; 935/18, 27, 31, 34, 38, 55, 62, 70, 72, 81 [IMAGE AVAILABLE]

66. 5,294,616, Mar. 15, 1994, Fibrinogen receptor antagonists; Mark E. Duggan, et al., 514/255, 80, 82, 85, 183, 210, 211, 299, 311, 326, 331, 377, 385, 391, 394, 428, 461, 501, 513, 529, 530, 533, 545, 547, 549, 561, 562, 563, 599, 609, 616; 544/232, 398, 400; 546/23, 112, 162, 221, 227, 233, 248, 279.1; 548/175, 567, 568, 950; 549/487; 558/170, 391; 560/9, 29, 41, 106, 107, 119, 122, 125, 168; 562/125, 501, 504, 507 [IMAGE AVAILABLE]

67. 5,292,756, Mar. 8, 1994, Novel sulfonamide fibrinogen receptor antagonists; Mark E. Duggan, et al., 514/331, 183, 210, 255, 318, 326, 332, 333, 336, 340, 341, 342, 343, 374, 376, 381, 383, 397, 401, 422;

540/1, 544; 544/358, 359, 360, 366, 367, 372; 546/22, 193, 207, 208, 209, 210, 212, 213, 216, 218, 221, 222, 225, 232, 255, 256, 276.4, 280.4; 548/112, 237, 238, 253, 254, 266.6, 314.7, 315.1, 316.7; 564/47, 84, 92
[IMAGE AVAILABLE]

68. 5,266,683, Nov. 30, 1993, Osteogenic proteins; Hermann Oppermann, et al., 530/326, 327, 328, 350, 395, 840 [IMAGE AVAILABLE]

69. 5,266,327, Nov. 30, 1993, Enhanced suturing and means therefor; Michael V. Agrez, 424/426, 422, 423; 514/2; 530/300, 330, 350; 606/228, 230 [IMAGE AVAILABLE]

70. 5,258,494, Nov. 2, 1993, Osteogenic proteins; Hermann Oppermann, et al., 530/326; 435/69.1, 172.3; 530/327, 328, 395, 840 [IMAGE AVAILABLE]

71. 5,250,302, Oct. 5, 1993, Osteogenic devices; Hermann Oppermann, et al., 424/422, 423, 426; 435/252.3; 536/23.5, 24.31 [IMAGE AVAILABLE]

72. 5,239,058, Aug. 24, 1993, Proteins having anticoagulant properties; George P. Vlasuk, et al., 530/324, 334, 354, 384 [IMAGE AVAILABLE]

73. 5,227,490, Jul. 13, 1993, Fibrinogen receptor antagonists; George D. Hartman, et al., 514/317, 329, 330, 331; 546/224, 225, 229, 233, 237 [IMAGE AVAILABLE]

74. 5,219,554, Jun. 15, 1993, Hydrated **biodegradable** superparamagnetic metal oxides; Ernest V. Groman, et al., 424/9.32; 128/653.4; 436/173 [IMAGE AVAILABLE]

75. 5,202,120, Apr. 13, 1993, Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes; Jerry Silver, et al., 424/93.7, 425, 570; 435/368 [IMAGE AVAILABLE]

76. 5,116,615, May 26, 1992, Method for treating benign prostatic hypertrophy; Muharrem Gokcen, et al., 424/94.2, 94.21, 94.6, 94.61, 94.62, 94.63, 94.64, 94.65, 94.67 [IMAGE AVAILABLE]

77. 5,108,759, Apr. 28, 1992, Endothelial envelopment drug carriers; David F. Ranney, 424/493, 9.32, 9.322, 85.2, 450, 460, 461, 463, 469, 488, 499; 428/402.2, 402.24; 436/829; 514/963, 965 [IMAGE AVAILABLE]

78. 5,108,753, Apr. 28, 1992, Osteogenic devices; Thangavel Kuberasampath, et al., 424/422, 423, 426, 428; 514/2, 21; 530/326, 327, 840; 623/11, 16 [IMAGE AVAILABLE]

79. 5,069,216, Dec. 3, 1991, Silanized **biodegradable** super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract; Ernest V. Groman, et al., 424/9.322; 128/653.4 [IMAGE AVAILABLE]

80. 5,011,691, Apr. 30, 1991, Osteogenic devices; Hermann Oppermann, et al., 424/423, 426; 514/2, 21; 530/350, 395, 840 [IMAGE AVAILABLE]

81. 4,997,443, Mar. 5, 1991, Transplantable artificial tissue and process; Bennie J. Walthall, et al., 623/11; 435/177, 182; 623/66 [IMAGE AVAILABLE]

82. 4,968,590, Nov. 6, 1990, Osteogenic proteins and polypeptides; Thangavel Kuberasampath, et al., 530/326, 327, 328, 395, 840 [IMAGE AVAILABLE]

83. 4,951,675, Aug. 28, 1990, ****Biodegradable**** superparamagnetic metal oxides as contrast agents for MR imaging; Ernest V. Groman, et al., 424/9.32; 128/653.4; 424/9.322; 648; 436/173; 600/12 [IMAGE AVAILABLE]

84. 4,925,678, May 15, 1990, Endothelial envelopment drug carriers; David F. Ranney, 424/493, 9.322, 85.2, 450, 460, 461, 463, 469, 488, 499; 428/402.2, 402.24; 436/829; 514/963, 965 [IMAGE AVAILABLE]

85. 4,902,295, Feb. 20, 1990, Transplantable artificial tissue; Bennie J. Walthall, et al., 623/11; 424/530, 556; 435/178; 623/12, 66 [IMAGE AVAILABLE]

86. 4,892,733, Jan. 9, 1990, ****Biodegradable**** synthesis polypeptide and its therapeutic use; Daniel Bichon, et al., 424/422, 425, 426, 445, 450; 528/328; 530/300, 333; 623/11, 16, 66 [IMAGE AVAILABLE]

87. 4,827,945, May 9, 1989, Biologically degradable superparamagnetic materials for use in clinical applications; Ernest V. Groman, et al., 424/9.32; 128/653.4; 424/9.322; 600/12 [IMAGE AVAILABLE]

=> log y

U.S. Patent & Trademark Office LOGOFF AT 10:16:06 ON 20 OCT 1997

+++
OK
ATHZ
OK

FILE 'HOME' ENTERED AT 13:31:13 ON 20 OCT 1997

=> index bioscience

49 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s fibrin and drug(5w)deliv? and (antibod? or immunoglo?)

14 FILES HAVE ONE OR MORE ANSWERS, 49 FILES SEARCHED IN STNINDEX

L1 QUE FIBRIN AND DRUG(5W) DELIV? AND (ANTIBOD? OR IMMUNOGLO?)

=> d rank

F1 97 USPATFULL

F2 54 DRUGU

F3 41 DDFU

F4 5 CAPLUS

F5 5 CJACS

F6 3 BIOSIS

F7 1 BIOBUSINESS

F8 1 EMBASE

F9 1 LIFESCI

F10 1 PHIN

F11 1 PROMT

F12 1 TOXLIT

F13 1 WPIDS

F14 1 WPINDEX

=> s l1

TOTAL FOR ALL FILES

L13 74 L1

=> dup rem l13

PROCESSING COMPLETED FOR L13

L14 69 DUP REM L13 (5 DUPLICATES REMOVED)

=> focus l14

PROCESSING COMPLETED FOR L14

L15 69 FOCUS L14 1-

=> d 1-69

L15 ANSWER 1 of 69 COPYRIGHT 1997 ACS

AN 91:12911 CJACS

SO Bioconjugate Chemistry, (1991), 2(5), 301-308. CODEN: BCCHES. ISSN:
1043-1802

TI Conjugation of Plasminogen Activators and ***Fibrin*** -Specific
Antibodies To Improve Thrombolytic Therapeutic Agents

AU (1) Hayzer, David J.; (2) Lubin, Ira M.; (3) Runge, Marschall S. (*)

CS (1,2,3) Division of Cardiology, Drawer LL, Emory University School of
Medicine, Atlanta, Georgia 30322

L15 ANSWER 2 OF 69 CAPLUS COPYRIGHT 1997 ACS

AN 1987:451648 CAPLUS

DN 107:51648

TI Coimmobilization of streptokinase and of ***antibodies*** to
collagen on the surface of erythrocytes: local lysis of the
fibrin clot in the vicinity of the collagenous target

AU Muzykantov, V. P.; Sakharov, D. V.; Smirnov, M. D.; Samokhin, G. P.;
Smirnov, V. N.

CS Inst. Exp. Cardiol., Moscow, USSR

SO Biotekhnologiya (1986), (6), 89-95

CODEN: BTKNEZ

DT Journal

LA Russian

L15 ANSWER 3 of 69 COPYRIGHT 1997 ACS

AN 95:8515 CJACS

SO Biotechnology Progress, (1995), 11(3), 333-341. CODEN: BIPRET. ISSN:
8756-7938

TI Noncompetitive Immunoassays Using Bifunctional Unilamellar Vesicles
or Liposomes

AU (1) Singh, Anup K.; (2) Kilpatrick, Peter K.; (3) Carbonell, Ruben G.
(*)

CS (1,2,3) Department of Chemical Engineering, North Carolina State
University, Raleigh, North Carolina 27695-7904

L15 ANSWER 4 OF 69 CAPLUS COPYRIGHT 1997 ACS

AN 1986:520723 CAPLUS

DN 105:120723

TI Method and use for site-specific activation of substances

IN Haber, Edgar; Matsueda, Gary R.

PA General Hospital Corp., USA

SO Eur. Pat. Appl., 37 pp.

CODEN: EPXXDW

PI EP 187658 A2 860716

DS R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

AI EP 86-100130 860107

PRAI US 85-689851 850108

US 85-774469 850910

DT Patent

LA English

L15 ANSWER 5 OF 69 CAPLUS COPYRIGHT 1997 ACS

AN 1997:34219 CAPLUS

DN 126:54876

TI ***Fibrin*** (ogen) degradation and clot lysis by fibrinolytic
matrix metalloproteinase
IN Bini, Alessandra
PA New York Blood Center, Inc., USA; Bini, Alessandra
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
PI WO 9636227 A1 961121
DS W: AU, CA, CN, JP, US
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE
AI WO 96-US7188 960517
PRAI US 95-446887 950517
DT Patent
LA English

L15 ANSWER 6 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 91-51887 DRUGU P G
TI Increased ***Fibrin*** Specificity of t-PA and u-PA Inferred by
Bispecific Monoclonal ***Antibodies*** , as Measured Using a
Novel Assay Method.
AU Bos R; Koolwijk P; Nieuwenhuizen W
LO Leiden, Netherlands
SO Thromb.Haemostasis (65, No. 6, 779, 1991)
CODEN: THHADQ ISSN: 0340-6245
AV Gaubius Laboratory, IVVO-TNO, Leiden, The Netherlands.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 7 OF 69 CAPLUS COPYRIGHT 1997 ACS
AN 1994:27036 CAPLUS
DN 120:27036
TI Acoustically reflective liposomes and methods to make and use them
IN Lanza, Gregory M.; Onyuksel, M. Hayat; Klegerman, Melvin E.; Vonesh,
Michael J.; McPherson, David L.
PA Northwestern University, USA
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
PI WO 9320802 A1 931028
DS W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AI WO 93-US3291 930408
PRAI US 92-865480 920409
DT Patent

LA English

L15 ANSWER 8 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 91-51886 DRUGU P

TI Targeting with Bispecific Monoclonal ***Antibodies*** Enhances
the Lysis of Plasma Clots by tcu-PA and scu-PA.

AU Bos R; Nieuwenhuizen W

LO Leiden, Netherlands

SO Thromb.Haemostasis (65, No. 6, 779, 1991)

CODEN: THHADQ ISSN: 0340-6245

AV Gaubius Laboratory, IVVO-TNO, Leiden, The Netherlands.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 9 OF 69 TOXLIT

AN 86:83671 TOXLIT

DN CA-105-120723W

TI Method and use for site-specific activation of substances.

AU Haber E; Matsueda GR

SO (1986). Eur. Pat. Appl. PATENT NO. 187658 07/16/86 (General Hospital
Corp.).

CY United States

DT Patent

FS CA

LA English

OS CA 105:120723

EM 8610

L15 ANSWER 10 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 92-14963 DRUGU P G

TI Enhancement of Clot Lysis In Vitro and In Vivo with a Bispecific
Monoclonal ***Antibody*** Directed against Human ***Fibrin***
and against Urokinase-Type Plasminogen Activator.

AU Kurokawa T; Iwasa S; Kakinuma A; Stassen J M; Lijnen H R; Collen D

CS Takeda

LO Louvain, Belgium; Osaka, Japan

SO Thromb.Haemostasis (66, No. 6, 684-93, 1991) 5 Fig. 5 Tab. 42 Ref.

CODEN: THHADQ ISSN: 0340-6245

AV Center for Thrombosis and Vascular Research, University of Leuven,
Campus Gasthuisberg, B-3000 Leuven, Belgium.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 11 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 90-05887 DRUGU P

TI Biochemical Properties of Conjugates of Urokinase-Type Plasminogen
Activator with a Monoclonal ***Antibody*** Specific for
Crosslinked Human ***Fibrin*** .

AU Dewerchin M; Lijnen H R; Mol M de; Collen D

LO Louvain, Belgium

SO Thromb.Haemostasis (62, No. 1, 541, 1989)

CODEN: THHADQ ISSN: 0340-6245

AV Center for Thrombosis and Vascular Research, University of Leuven,
Leuven, Belgium.

LA English

DT Journal

FA AB; LA; CT; MPC

FS Literature

L15 ANSWER 12 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 93-15125 DRUGU P G

TI Bispecific Monoclonal ***Antibodies*** Increase the
Fibrin -Specific Fibrinolytic Activity of Tissue-Type
Plasminogen Activator (tPA) and Urokinase-Type Plasminogen
Activator (uPA).

AU Bos R; Nieuwenhuizen W

LO Leiden, Netherlands

SO Ann.N.Y.Acad.Sci. (667, 428-30, 1992) 1 Fig. 1 Tab. 4 Ref.

CODEN: ANYAA9 ISSN: 0077-8923

AV Gaubius Laboratory, IVVO-TNO, P.O. Box 430, 2300 AK Leiden, The
Netherlands.

LA English

DT Journal

FA AB; LA; CT; MPC

FS Literature

L15 ANSWER 13 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 90-05329 DRUGU P G

TI Biochemical Properties of Conjugates of Urokinase-Type Plasminogen
Activator with a Monoclonal ***Antibody*** Specific for
Cross-Linked ***Fibrin*** .

AU Dewerchin M; Lijnen H R; Hoef B van; Cock F de; Collen D

LO Louvain, Belgium

SO Eur.J.Biochem. (185, No. 1, 141-49, 1989) 7 Fig. 2 Tab. 31 Ref.

CODEN: EJBCAI ISSN: 0014-2956

AV Center for Thrombosis and Vascular Research, Campus Gasthuisberg,

University of Leuven, B-3000 Leuven, Belgium.

LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 14 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 97-13306 DRUGU P G

TI In vitro targeting of ***antibody*** -conjugated echogenic
liposomes for site-specific ultrasonic image enhancement.

AU Demos S M; Onyuksel H; Gilbert J; Roth S I; Kane B; Jungblut P;
Pinto J V; McPherson D D; Klegerman M E

CS Univ.Illinois; Univ.Northwestern

LO Chicago, Ill., USA

SO J.Pharm.Sci. (86, No. 2, 167-71, 1997) 3 Fig. 2 Tab. 23 Ref.

CODEN: JPMSAE ISSN: 0022-3549

AV Department of Bioengineering, University of Illinois at Chicago,
Chicago, IL 60612, U.S.A. (H.O.).

LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 15 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 85-37591 DRUGU P

TI A Urokinase- ***Fibrin*** -Specific Monoclonal ***Antibody***
Conjugate Results in 100-Fold Enhanced Fibrinolysis in Vitro.

AU Bode C; Matsueda G R; Haber E

LO Boston, Massachusetts, United States

SO Clin.Res. (33, No. 2, Pt. 1, 544A, 1985)

CODEN: CLREAS ISSN: 0009-9279

AV Cardiac Unit, Massachusetts General Hospital, Boston, MA., U.S.A.

LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 16 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 94-50247 DRUGU P G

TI ***Fibrin*** -targeted recombinant hirudin inhibits
fibrin deposition on experimental clots more efficiently
than recombinant hirudin.

AU Bode C; Hudelmayer M; Mehwald P; Bauer S; Freitag M; Hodenberg E
von

CS Univ.Heidelberg; Univ.Harvard; Univ.Texas-A+M-Syst.

LO Heidelberg, Germany, West; Boston, Massachusetts, Galveston, Texas,
United States

SO Circulation (90, No. 4, 1956-63, 1994) 7 Fig. 27-Ref.

CODEN: CIRCAZ ISSN: 0009-7322

AV Medizinische Klinik III (Kardiologie), Begheimerstr 58, 69115
Heidelberg, Germany. (10 authors).

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 17 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 87-31583 DRUGU P

TI Thrombolysis by a ***Fibrin*** -Specific ***Antibody***
Fab'-Urokinase Conjugate.

AU Bode C; Runge M S; Newell J B; Matsueda G R; Haber E

LO Boston, Massachusetts, United States

SO J.Mol.Cell.Cardiol. (19, No. 4, 335-41, 1987) 3 Fig. 18 Ref.

CODEN: JMCDAV ISSN: 0022-2828

AV Cardiac Unit, Massachusettes General Hospital, Boston, MA 02114,
U.S.A.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 18 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 91-51883 DRUGU P

TI Enhancement of the Thrombolytic Potency of Single-Chain
Urokinase-Type Plasminogen Activator by Conjugation with a
Monoclonal ***Antibody*** Against Polymerized ***Fibrin*** .

AU Dewerchin M; Lijnen H R; Holvoet P; Stassen J M; Gaffney P; Collen
D

LO Louvain, Belgium

SO Thromb.Haemostasis (65, No. 6, 778, 1991)

CODEN: THHADQ ISSN: 0340-6245

AV Center for Thrombosis and Vascular Research, University of Leuven,
Leuven, Belgium.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 19 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 90-19248 DRUGU T P

TI Bispecific ***Antibody** : A Tool for Diagnosis and Treatment
of Disease.

AU Songsivilai S; Lachmann P J

LO Cambridge, United Kingdom

SO Clin.Exp.Immunol. (79, No. 3, 315-21, 1990) 1 Fig. 73 Ref.

CODEN: CEXIAL ISSN: 0009-9104

AV Molecular Immunopathology Unit, MRC Centre, Cambridge CB2 2QH,
England.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 20 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 90-04948 DRUGU P

TI Thrombolytic Properties of Chimeric Proteins Consisting of Domains
of scu-PA and t-PA and of Chemical Conjugates of scu-PA with
Monoclonal Anti- ***Fibrin*** ***Antibody*** .

AU Collen D; Stassen J M; Dewerchin M; Lijnen H R

LO Louvain, Belgium

SO Thromb.Haemostasis (62, No. 1, 484, 1989)

CODEN: THHADQ ISSN: 0340-6245

AV Center for Thrombosis, University of Leuven, Leuven, Belgium.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 21 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 86-24957 DRUGU P G

TI Better Targetted Thrombolysis. A Conjugate of a ***Fibrin***
-Specific Monoclonal ***Antibody*** and Urokinase.

AU Bode C; Matsueda G R; Haber E

LO Boston, Massachusetts, United States

SO Z.Kardiol. (75, Suppl. 1, 105, 1986)

CODEN: ZKRDAX ISSN: 0300-5860

AV Massachusetts General Hospital, Boston, MA, U.S.A.

LA German

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 22 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 97-34425 DRUGU B P

TI In vivo thrombolytic properties of urokinase directed by a

bispecific monoclonal * *antibody*** for urokinase and for
human * fibrin*** .

AU Wu H Z; Li J Z; Peng L; Liu H Z; Wu W J
CS Chinese-Acad.Med.Sci.
LO Tianjin, China
SO Thromb.Haemostasis (Suppl., 504, 1997)
CODEN: THHADQ ISSN: 0340-6245
AV Institute of Hematology, Chinese Academy of Medical Sciences,
Tianjin 300020, China.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 23 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 90-33599 DRUGU P C G
TI A Hybrid Molecule from Prourokinase and a ***Fibrin*** Specific
Monoclonal ***Antibody*** Fraction is as Thrombolytically
Active as Prourokinase In Vitro and In Vivo.
AU Bode C; Eberle T; Runge M; Haber E; Kuebler W
LO Heidelberg, Germany, West
SO Klin.Wochenschr. (68, Suppl. 19, 179-80, 1990)
CODEN: KLWOAZ
AV Medizinische Klinik III (Kardiologie), Bergheimer Strasse 58,
D-6900 Heidelberg, West Germany.
LA German
DT Journal
FA AB; LA; CT; MPC
FS Literature

L15 ANSWER 24 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 90-17971 DRUGU P G
TI Effect of ***Fibrin*** -Targeting on Clot Lysis with
Urokinase-Type Plasminogen Activator.
AU Lijnen H R; Dewerchin M; Cock F de; Collen D
LO Louvain, Belgium
SO Thromb.Res. (57, No. 3, 333-42, 1990) 2 Fig. 1 Tab. 30 Ref.
CODEN: THBRAA ISSN: 0049-3848
AV Center for Thrombosis and Vascular Research, University of Leuven,
Leuven, Belgium.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 25 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 86-22372 DRUGU P

TI Targeted Thrombolysis with a ***Fibrin ** -Specific
***Antibody** -Urokinase Conjugate.

AU Bode C; Matsueda G; Haber E

LO Boston, Massachusetts, United States

SO Circulation (72, No. 4, Pt. 2, 192, 1985)

CODEN: CIRCAZ ISSN: 0009-7322

AV Massachusetts General Hospital, Boston, MA, U.S.A.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 26 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 91-02470 DRUGU P G

TI Thrombolytic and Pharmacokinetic Properties of a Conjugate of
Recombinant Single-Chain Urokinase-Type Plasminogen Activator with
a Monoclonal ***Antibody*** Specific for Cross-Linked
Fibrin in a Baboon Venous Thrombosis Model.

AU Collen D; Dewerchin M; Rapold H J; Lijnen H R; Stassen J M

LO Louvain, Belgium

SO Circulation (82, No. 5, 1744-53, 1990) 4 Fig. 3 Tab. 31 Ref.

CODEN: CIRCAZ ISSN: 0009-7322

AV Center for Thrombosis and Vascular Research, K.U. Leuven, Campus
Gasthuisberg, O & N Herestraat 49, B-3000 Leuven, Belgium.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 27 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 86-18912 DRUGU P

TI Immunofibrinolysis: Human ***Fibrin*** -Specific Monoclonal
Antibodies as Carriers for Fibrinolytic Agents.

AU Ito R K; Davis G L; Yunis E J; Houranieh A; Statland B E

LO Boston, Massachusetts, United States

SO Thromb.Haemostasis (54, No. 1, 276, 1985)

CODEN: THHADQ ISSN: 0340-6245

AV University Hospital, Northeastern Univ., Dana-Farber Cancer Inst.,
Boston, MA 02118, U.S.A.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 28 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 85-43944 DRUGU P

TI ***Antibody*** -Directed Urokinase: A Specific Fibrinolytic Agent.

AU Bode C; Matsueda G R; Hui K Y; Haber E

LO Boston, Massachusetts, United States

SO Science (229, No. 4715, 765-67, 1985) 2 Fig. 14 Ref.

CODEN: SCIEAS ISSN: 0036-8075

AV Cardiac Unit, Massachusetts General Hospital, Boston 02114, U.S.A.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 29 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 94-07255 DRUGU P

TI ***Fibrin*** -Targeted or Platelet-Targeted Recombinant Hirudin Inhibits ***Fibrin*** Deposition on Experimental Clots More Efficiently Than Untargeted Hirudin.

AU Bode C; Freitag M; Mewald P; Hudelmayer M; Ruef J; Runge M S

CS Univ.Heidelberg; Univ.Emory

LO Heidelberg, Germany, West; Atlanta, Georgia, Boston, Massachusetts, United States

SO Circulation (88, No. 4, Pt. 2, 1417, 1993)

CODEN: CIRCAZ ISSN: 0009-7322

AV University of Heidelberg, Germany. (7 authors).

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 30 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 87-48678 DRUGU P

TI Characterization of an ***Antibody*** -Urokinase Conjugate. A Plasminogen Activator Targeted to ***Fibrin*** .

AU Bode C; Runge M S; Newell J B; Matsueda G R; Haber E

LO Boston, Massachusetts, United States

SO J.Biol.Chem. (262, No. 22, 10819-23, 1987) 4 Fig. 22 Ref.

CODEN: JBCHA3 ISSN: 0021-9258

AV Massachusetts General Hospital, Boston, MA 02114, U.S.A.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 31 OF 69 BIOSIS COPYRIGHT 1997 BIOSIS

AN 88:202570 BIOSIS

DN BA85:103916

TI CONJUGATION TO AN ANTIFIBRIN MONOCLONAL ***ANTIBODY***
ENHANCES

THE FIBRINOLYTIC POTENCY OF TISSUE PLASMINOGEN ACTIVATOR IN-VITRO.

AU RUNGE M S; BODE C; MATSUEDA G R; HABER E

CS MASS. GENERAL HOSP., HARVARD MED. SCH., BOSTON, MA 02114.

SO BIOCHEMISTRY 27 (4). 1988. 1153-1157. CODEN: BICHAW ISSN: 0006-2960

LA English

L15 ANSWER 32 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 92-32174 DRUGU P G

TI Thrombolytic and Pharmacokinetic Properties of an Immunoconjugate
of Single-Chain Urokinase-Type Plasminogen Activator (u-PA) and a
Bispecific Monoclonal ***Antibody*** Against ***Fibrin***
and Against u-PA in Baboons.

AU Imura Y; Stassen J M; Kurokawa T; Iwasa S; Lijnen H R; Collen

CS Takeda

LO Louvain, Belgium; Osaka, Japan

SO Blood (79, No. 9, 2322-29, 1992) 4 Fig. 3 Tab. 32 Ref.

CODEN: BLOOAW ISSN: 0006-4971

AV Center for Thrombosis and Vascular Research, University of Leuven,
Campus Gasthuisberg, O + N, Herestraat 49, B-3000 Leuven, Belgium.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 33 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 92-01908 DRUGU P

TI Characterization of a Single-Chain Recombinant Plasminogen
Activator Consisting of a Fv Fragment Derived from a D-Dimer
Specific ***Antibody*** and Low Molecular Weight Single-Chain
Urokinase (rscu-Pa-32k).

AU Holvoet P; Laroche Y; Lijnen H R; Demarsin E; Mathijssens G; Collen
D

CS Plant-Genetic-Systems

LO Louvain, Ghent, Belgium

SO Thromb.Haemostasis (65, No. 6, 1195, 1991)

CODEN: THHADQ ISSN: 0340-6245

AV Center for Thrombosis and Vascular Research, K.U. Leuven, Belgium.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 34 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 88-07893 DRUGU P

TI ***Antibody*** -Enhanced Thrombolysis: Targeting of Tissue
Plasminogen Activator In Vivo.

AU Runge M S; Bode C; Matsueda G R; Haber E

LO Boston, Massachusetts, United States

SO Proc.Natl.Acad.Sci.U.S.A. (84, No. 21, 7659-62, 1987) 5 Fig. 17
Ref.

CODEN: PNASA6 ISSN: 0027-8424

AV Cardiac Unit, Massachusetts General Hospital, Boston, MA 02114,
U.S.A.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 35 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 96-47125 DRUGU P

TI Enhanced antithrombotic potency of ***fibrin*** -targeted
recombinant hirudin in a non-human primate model.

AU Bode C; Mehwald P; Peter K; Nordt T; Harker L A; Hanson S R; Runge
M S

CS Univ.Heidelberg; Univ.Emory; Univ.Texas-Syst.

LO Heidelberg, Ger., Atlanta, Ga.; Galveston, Tex., USA

SO Eur.Heart J. (17, Abstr.Suppl., 461, 1996)

CODEN: EHJODF ISSN: 0195-668X

AV University of Heidelberg, Heidelberg, Germany.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 36 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 94-50254 DRUGU P G

TI Local ***drug*** ***delivery*** for the prevention of
restenosis: fact, fancy, and future.

AU Lincoff A M; Topol E J; Ellis S G

CS Cleveland-Clinic-Found.

LO Cleveland, Ohio, United States

SO Circulation (90, No. 4, 2070-84, 1994) 5 Fig. 122 Ref.

CODEN: CIRCAZ ISSN: 0009-7322

AV No Reprint Address

LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 37 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 93-15121 DRUGU P G
TI Targeting of Thrombolytic Agents: Current State of Knowledge and Perspectives.
AU Torchilin V P
LO East Charlestown, Massachusetts, United States
SO Ann.N.Y.Acad.Sci. (667, 404-16, 1992) 7 Fig. 2 Tab. 48 Ref.

CODEN: ANYAA9 ISSN: 0077-8923
AV Center For Imaging and Pharmaceutical Research, Massachusetts General Hospital, East Charlestown, Massachusetts 02129, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 38 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 96-06320 DRUGU P G
TI Enhanced antithrombotic potency of ***fibrin*** -targeted recombinant hirudin in a non-human primate model.
AU Bode C; Mehwald P; Schmedtje J; Harker L A; Hanson S R; Runge M S
CS Univ.Heidelberg; Univ.Emory; Univ.Texas-Syst.
LO Heidelberg, Ger.; Atlanta, Ga.; Galveston, Tex., USA
SO Circulation (92, No. 8, Suppl., I-685, 1995)

CODEN: CIRCAZ ISSN: 0009-7322
AV University of Heidelberg, Germany.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 39 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 93-01293 DRUGU P
TI The Potential Improvement of Thrombolytic Therapy by Targeting With Specific Monoclonal ***Antibodies*** : Why They are Used and How are They Made.
AU Bos R; Nieuwenhuizen W
LO Leiden, Netherlands
SO Biotherapy (5, No. 3, 187-99, 1992) 6 Fig. 87 Ref. ISSN: 0921-299X
AV IVVO-TNO, Gaubius Laboratory, P.O. Box 430, 2300 AK Leiden, The

Netherlands.

LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 40 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 88-02935 DRUGU P G
TI Construction and Expression of a Recombinant ***Antibody***
-Targeted Plasminogen Activator.
AU Schnee J M; Runge M S; Matsueda G R; Hudson N W; Seidman J G; Haber
E

LO Boston, Massachusetts, United States
SO Proc.Natl.Acad.Sci.U.S.A. (84, No. 19, 6904-08, 1987) 4 Fig. 26
Ref.
CODEN: PNASA6 ISSN: 0027-8424
AV Cardiac Unit, Department of Medicine, Massachusetts General
Hospital, Boston, MA 02114, U.S.A. (T. Quertermous, 7 authors).
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L15 ANSWER 41 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 87-01148 DRUGU P
TI Immunotargeting of Erythrocyte-bound Streptokinase Provides Local
Lysis of a ***Fibrin*** Clot.
AU Muzykantov V R; Sakharov D V; Smirnov M D; Samokhin G P; Smirnov V
N
LO Moscow, Russia
SO Biochim.Biophys.Acta G (884, No. 2, 355-62, 1986) 6 Fig. 2 Tab. 31
Ref. ISSN: 0304-4165
AV Institute of Experimental Cardiology, USSR Cardiology Research
Center, 3rd Cherepkovskaja Str. 15a, Moscow, 121552, U.S.S.R.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 42 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 93-21327 DRUGU P G
TI Importance of Appropriate ***Antibody*** Targeting of
Fibrinolytic Agents for Enhanced Antithrombotic Efficacy in an
In-Vivo Model of Thrombosis.
AU More R S; Underwood M J; Pringle S; Brack M J; Gershlick A H; De

Bono D P

LO Leicester, United Kingdom

SO Clin.Sci. (84, No. 3, 17P, 1993) 1 Tab.

CODEN: CSCIAE ISSN: 0143-5221

AV Cardiology Department, University of Leicester, Leicester LE3 9QP,
England.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 43 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 91-48252 DRUGU P G

TI Effect of Chemical Conjugation of Recombinant Single-Chain

Urokinase-Type Plasminogen Activator with Monoclonal Antiplatelet

Antibodies on Platelet Aggregation and on Plasma Clot Lysis

In Vitro and In Vivo.

AU Dewerchin M; Lijnen H R; Stassen J M; Cock F de; Quertermous T;
Ginsberg M H

LO Louvain, Belgium; Boston, Massachusetts, Louisiana, Jolla,
California, United States

SO Blood (78, No. 4, 1005-18, 1991) 8 Fig. 4 Tab. 27 Ref.

CODEN: BLOOAW ISSN: 0006-4971

AV Center for Thrombosis and Vascular Research, K.U. Leuven, Campus
Gasthuisberg, O & N, Herestraat 49, B-3000 Leuven, Belgium. (Collen
D, 8 authors).

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 44 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 97-13686 DRUGU P

TI Antithrombotic potency of hirudin is increased in nonhuman primates
by ***fibrin*** targeting.

AU Bode C; Hanson S R; Schmedtje J F; Haber E; Mehwald P; Kelly A B;
Harker L A; Runge M S

CS Univ.Texas-Syst.; Univ.Emory; Univ.Harvard

LO Galveston, Tex., Atlanta, Ga.; Boston, Mass., USA; Heidelberg, Ger.

SO Circulation (95, No. 4, 800-804, 1997) 2 Fig. 21 Ref.

CODEN: CIRCAZ ISSN: 0009-7322

AV Division of Cardiology, University of Texas Medical Branch, 301
University Blvd, Route 0553, Galveston, TX 77555-0533, U.S.A.
(M.S.R.).

LA English

DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 45 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 93-02532 DRUGU P
TI A Monoclonal Conjugate with Powerful Antiplatelet and Fibrinolytic
Action that Localises to Endothelium.
AU More R S; Pringle S; Brack M; Gershlick A H
LO Leicester, United Kingdom
SO Eur.Heart J. (13, Abstr.Suppl., 265, 1992)
CODEN: EHJODF ISSN: 0195-668X

AV Department of Cardiology, Glenfield General Hospital, Leicester,
England.

LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 46 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 91-29851 DRUGU P G
TI A Recombinant Prourokinase Antifibrin ***Antibody*** (rPUK-AB)
Molecule Shows Increased Thrombolysis In-Vivo.
AU Bode C; Freitag M; Haber E; Runge M S
LO Heidelberg, Germany, West; Boston, Massachusetts, Atlanta, Georgia,
United States
SO Z.Kardiol. (80, Suppl. 3, 31, 1991)
CODEN: ZKRDAX ISSN: 0300-5860

AV Med.Klinik III, Univ. Heidelberg, Germany.
LA German
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 47 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 97-21145 DRUGU P
TI A novel ***fibrin*** targeted magnetic resonance imaging agent.
AU Lanza G M; Lorenz C H; Fischer S E; Scott M J; Abendschein D R;
Cacheris W P; Kaufman R J; Gaffney P J; Wickline S A
CS Univ. Washington
LO St Louis, Mo, USA; Potters Bar, U.K.
SO J.Invest.Med. (45, No. 3, 217A, 1997) 1 Fig. ISSN: 1081-5589
AV Washington University, St. Louis, MO., U.S.A. A
LA English
DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 48 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 91-26546 DRUGU P

TI Targetting of Single-Chain Urokinase Plasminogen Activator by
Conjugation to an Antiplatelet ***Antibody*** Results in
Enhanced Clot Lysis.

AU Bode C; Nordt T; Detlefs Bartels U; Runge M S; Arens M; Kuebler W

LO Heidelberg, Germany, West

SO Clin.Res. (39, No. 2, 196A, 1991)

CODEN: CLREAS ISSN: 0009-9279

AV Medical Clinic III, University of Heidelberg, Germany. (7 authors).

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 49 OF 69 PROMT COPYRIGHT 1997 IAC

ACCESSION NUMBER: 91:310013 PROMT

TITLE: Studies of Surface-passivated Lenses Examine
Biocompatibility

SOURCE: Ophthalmology Times, (1 Jun 1991) pp. 48.
ISSN: 0193-032X.

WORD COUNT: 578

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L15 ANSWER 50 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 96-05765 DRUGU P

TI Protein loop grafting to construct a variant of tissue-type
plasminogen activator that binds platelet integrin α IIb β 3.

AU Smith J W; Tachias K; Madison E L

CS Scripps-Res.Inst.; La-Jolla-Cancer-Res.Found.

LO La Jolla, Cal., USA

SO J.Biol.Chem. (270, No. 51, 30486-90, 1995) 4 Fig. 2 Tab. 38 Ref.

CODEN: JBCHA3 ISSN: 0021-9258

AV Scripps Research Inst., Dept. of Vascular Biology (VB-1), 10666N.
Torrey Pines Rd., La Jolla, CA 92037, U.S.A. (E.L.M.).

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 51 OF 69 LIFESCI COPYRIGHT 1997 CSA

AN 97:63014 LIFESCI

TI Method and compositions for the direct concentrated delivery of
passive immunity

CS MEDICAL SCIENCES RESEARCH INSTITUTE

SO (1996) . US Patent 5505945; US Cl. 424/164.1 424/130.1 424/150.1
424/163.1 424/165.1 424/169.1 424/170.1 530/387.1 530/388.1
530/388.2 530/388.4 530/389.1 530/389.5.

DT Patent

FS W3

LA English

L15 ANSWER 52 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 96-17413 DRUGU P G

TI Novel ultrasonic contrast agent targeted to D-Dimer using DD-3B6
monoclonal F(ab) in vitro.

AU Lanza G M; Wallace K D; Eisenberg P R; Scott M J; Cacheris W P;
Christy D H; Sharkey A M; Miller J G; Wickline S A

CS Univ. Washington

LO St. Louis, Mo., USA

SO J. Am. Coll. Cardiol. (27, No. 2, Suppl. A, 243A, 1996)
CODEN: JACCDI ISSN: 0735-1097

AV Jewish and Barnes Hospitals at Washington University, St Louis, MO,
U.S.A.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 53 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 93-46892 DRUGU B P

TI Hirudin Targeted to the Site of Thrombin Action: a New
Antithrombotic Agent.

AU Bode C; Hudelmayer M; Freitag M; Runge M S; Haber E

LO Heidelberg, Germany, West; Atlanta, Georgia, Boston, Massachusetts,
United States

SO Thromb. Haemostasis (69, No. 6, 1298, 1993)
CODEN: THHADQ ISSN: 0340-6245

AV Dept of Cardiology, University of Heidelberg, Germany.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 54 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 93-44962 DRUGU P

TI Thrombolytic Profiles of Clot-Targeted Plasminogen Activators:

Parameters Determining Potency and Initial and Maximal Rates.

AU Holvoet P; Dewerchin M; Stassen J M; Lijnen H R; Gaffney P J;
Collen D

LO Louvain, Belgium; United Kingdom

SO Thromb.Haemostasis (69, No. 6, 842, 1993)

CODEN: THHADQ ISSN: 0340-6245

AV Center for Thrombosis and Vascular Research, Univ. Leuven, Belgium.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 55 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 92-40320 DRUGU P G

TI A Novel Monoclonal Conjugate with Powerful Antiplatelet and
Fibrinolytic Properties Which Localises to Damaged Endothelium.

AU More R S; Brack M; Pringle S; Gershlick A H

LO Leicester, United Kingdom

SO Br.Heart J. (68, No. 1, 143, 1992)

CODEN: BHJUAU ISSN: 0007-0769

AV Glenfield General Hospital, Leicester, England.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 56 OF 69 COPYRIGHT 1997 ACS

AN 93:70 CJACS

SO Chemical Reviews, (1992), 92(8), 1799-1818. CODEN: CHREAY. ISSN:
0009-2665

TI Protein Adsorption and Inactivation on Surfaces. Influence of
Heterogeneities

AU (1) Sadana, Ajit

CS (1) Chemical Engineering Department, University of Mississippi,
University, Mississippi 38677-9740

L15 ANSWER 57 OF 69 BIOSIS COPYRIGHT 1997 BIOSIS

AN 90:436630 BIOSIS

DN BR39:84491

TI IMPROVING ON NATURE ***ANTIBODY*** -TARGETED ENZYMES.

AU BODE C; RUNGE M S; HABER E

CS SQUIBB INST. MED. RES., P.O. BOX 4000, PRINCETON, NJ 08543-4000, USA.

SO CRUSE, J. M. AND R. E. LEWIS, JR. (ED.). THE YEAR IN IMMUNOLOGY, VOL.

6. THE YEAR IN IMMUNOLOGY 1989-90: MOLECULES AND CELLS OF IMMUNITY.

VI+284P. S. KARGER AG: BASEL, SWITZERLAND; NEW YORK, NEW YORK, USA.

ILLUS. 0 (0). 1990. 185-196. CODEN: YEIMEY ISBN: 3-8055-5084-7

LA English

L15 ANSWER 58 OF 69 EMBASE COPYRIGHT 1997 ELSEVIER SCI. B.V.

AN 87151921 EMBASE

TI Interactions of polymerizable phosphatidylcholine vesicles with
blood components: relevance to biocompatibility.

AU Bonte F.; Hsu M.J.; Papp A.; et al.

CS Department of Pharmacology, University of Texas Medical School,
Houston TX 77225, United States

SO BIOCHIM. BIOPHYS. ACTA, (1987) 900/1 (1-9).

CODEN: BBBMBS

CY Netherlands

FS 029 Clinical Biochemistry

LA English

L15 ANSWER 59 OF 69 COPYRIGHT 1997 PJB

AN 91:1817 PHIN

DN S00264884

DED 6 Feb 1991

TI Temple University to license antiplatelet Research & Development
(R&D)

SO Scrip (1991) No. 1588 p21

DT Newsletter

FS FULL

L15 ANSWER 60 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 92-35360 DRUGU P

TI A Novel Monoclonal Conjugate which Localises to Damaged Endothelium
and has Powerful Antiplatelet and Fibrinolytic Properties.

AU More R S; Pringle S; Gershlick A H

LO Leicester, United Kingdom

SO Br.J.Haematol. (80, Suppl. 1, 5, 1992)

CODEN: BJHEAL ISSN: 0007-1048

AV Glenfield General Hospital, Leicester, England.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 61 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 91-42255 DRUGU P

TI Platelet-Targeted Fibrinolysis Enhances Clot Lysis and Inhibits

Platelet Aggregation.

AU Bode C; Meinhardt G; Runge M S; Freitag M; Nordt T; Arens M
CS Bristol
LO Heidelberg, Germany, West; Atlanta, Georgia, Boston, Massachusetts,
Princeton, New Jersey, United States
SO Circulation (84, No. 2, 805-13, 1991) 8 Fig. 31 Ref.
CODEN: CIRCAZ ISSN: 0009-7322
AV Medizinische Klinik III (Kardiologie), Bergheimerstrasse 58, 6900
Heidelberg, Germany. (9 authors).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 62 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 91-17344 DRUGU T G S
TI Towards the Development of Improved Thrombolytic Agents.
AU Lijnen H R; Collen D
LO Louvain, Belgium
SO Br.J.Haematol. (77, No. 3, 261-66, 1991) 58 Ref.
CODEN: BJHEAL ISSN: 0007-1048
AV Center for Thrombosis and Vascular Research, K.U.L., Campus
Gasthuisberg, O & N, Herestraat 49, B-3000 Leuven, Belgium.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 63 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 91-13017 DRUGU P T S
TI New Horizons in the Treatment of Coronary Artery Thrombosis.
AU Runge M S
LO Atlanta, Georgia, United States
SO Am.J.Med.Sci. (301, No. 1, 21-27, 1991) 2 Fig. 52 Ref.
CODEN: AJMSA9 ISSN: 0002-9629
AV Division of Cardiology, Emory University, P.O. Drawer LL, Atlanta,
GA 30322, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 64 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 85-48203 DRUGU P G
TI Plasminogen Activator-Anti-Human Fibrinogen Conjugate.

AU Sevilla C L; Mahle N H; Boylan C M; Callewaert D M
CS Proteins-Int.
LO Rochester, Michigan, United States
SO Biochem.Biophys.Res.Comm. (130, No. 1, 91-96, 1985) 2 Fig. 2 Tab.
12 Ref.
CODEN: BBRC A9 ISSN: 0006-291X
AV Proteins International, 1858 Star Batt Dr., Rochester, Michigan
48063, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 65 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 95-20906 DRUGU T S G
TI Gastrointestinal effects of chimeric BR96-doxorubicin (DOX)
conjugate.
AU Saleh M; LoBuglio A; Sugarman S; Murray J; Onetto N; Warner G;
Mezza L; Davidson T; Grizzle W; Daniel C; LeBherz D; Healey D;
Baron T; Leeuwen D van; Canetta R; Hellstrom K
CS Univ.Alabama; Univ.Texas-M.D.Anderson-Cancer-Cent.; Bristol- Squibb
LO Ala., Houston, Tex.; Princeton, N.J., USA
SO Proc.Am.Assoc.Cancer Res. (36, 86 Meet., 483, 1995) ISSN:
0197-016X
AV University of Alabama, AL., U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L15 ANSWER 66 of 69 COPYRIGHT 1997 ACS
AN 95:4169 CJACS
SO Bioconjugate Chemistry, (1995), 6(2), 150-165. CODEN: BCCHE S. ISSN:
1043-1802
TI Functionalized Poly(ethylene glycol) for Preparation of Biologically
Relevant Conjugates
AU (1) Zalipsky, Samuel (*)
CS (1) Liposome Technology, Inc., 960 Hamilton Court, Menlo Park,
California 94025

L15 ANSWER 67 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
AN 88-04771 DRUGU P G
TI Encapsulation of Human Urokinase in Rabbit Erythrocytes and its
Disposition in the Circulation System in Rabbits.
AU Ito Y; Ogiso T; Iwaki M; Atago H

LO Osaka, Japan

SO J.Pharmacobiodyn. (10, No. 10, 550-56, 1987) 3 Fig. 2 Tab. 22 Ref.

CODEN: JOPHDQ ISSN: 0386-846X

AV Faculty of Pharmaceutical Sciences, Kinki University, Kowakae
3-4-1, Higashi-Osaka, 577, Japan.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 68 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 96-47806 DRUGU P

TI Site-specific thrombolysis with ReoPro.

AU Mitchell J F; Azrin M A; Alberghini T V; Fusco M; Bow L M; Fram D
B; Kiernan F J; McKay R G

CS Univ.Connecticut

LO Hartford; Farmington, Conn., USA

SO Circulation (94, No. 8, Suppl., I202, 1996) 1 Tab.

CODEN: CIRCAZ ISSN: 0009-7322

AV Hartford Hospital, Hartford, CT, U.S.A.

LA English

DT Journal

FA AB; LA; CT

FS Literature

L15 ANSWER 69 OF 69 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD

AN 84-04527 DRUGU T E

TI Glycaemic Control in Diabetic Patients by a Wearable Artificial
Endocrine Pancreas with a Needle-Type Glucose Sensor.

AU Shichiri M; Kawamori R; Goriya Y; Yamasaki Y; Hakui N; Abe H

LO Osaka, Japan

SO Diabetologia (25, No. 2, 194, 1983)

CODEN: DBTGAI ISSN: 0012-186X

AV Osaka University Medical School, Osaka, Japan.

LA English

DT Journal

FA AB; LA; CT

FS Literature

=> file uspatfull

FILE 'USPATFULL' ENTERED AT 13:38:45 ON 20 OCT 1997

=> s fibrin and drug(5w)deliv?(50a)(antibod? or immunoglo?)

L16 14 FIBRIN AND DRUG(5W)DELIV?(50A)(ANTIBOD? OR IMMUNOGLO?)

=> d 1-14

L16 ANSWER 1 OF 14 USPATFULL

AN 97:68157 USPATFULL

TI Immunotargeting of plasminogen activators to the pulmonary endothelium

IN Muzykantov, Vladimir R., Philadelphia, PA, United States

Barnathan, Elliot S., Havertown, PA, United States

PA Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

PI US 5653979 970805

AI US 95-413415 950330 (8)

DT Utility

LN.CNT 451

L16 ANSWER 2 OF 14 USPATFULL

AN 96:112986 USPATFULL

TI System of drug delivery to the lymphatic tissues

IN Papisov, Mikhail I., Boston, MA, United States

Brady, Thomas J., Winchester, MA, United States

PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

PI US 5582172 961210

AI US 95-375188 950118 (8)

RLI Continuation of Ser. No. US 92-917707, filed on 21 Jul 1992, now abandoned

DT Utility

LN.CNT 1652

L16 ANSWER 3 OF 14 USPATFULL

AN 96:3653 USPATFULL

TI Polypeptide linkers for production of biosynthetic proteins

IN Huston, James S., Chestnut Hill, MA, United States

Oppermann, Hermann, Medway, MA, United States

PA Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S. corporation)

PI US 5482858 960109

AI US 93-139171 931019 (8)

RLI Continuation of Ser. No. US 92-955399, filed on 1 Oct 1992, now patented, Pat. No. US 5258498 which is a continuation of Ser. No. US 89-342449, filed on 23 Jan 1989, now abandoned which is a continuation-in-part of Ser. No. US 87-52800, filed on 21 May 1987, now abandoned

DT Utility

LN.CNT 1846

L16 ANSWER 4 OF 14 USPATFULL

AN 96:3498 USPATFULL

TI Substituted polyamino, polycarboxy complexing agent dimers for MRI and X-ray contrast

IN Deutsch, Julius, Berlin, Germany, Federal Republic of
Gries, Heinz, Berlin, Germany, Federal Republic of
Klieger, Erich, Berlin, Germany, Federal Republic of
Niedballa, Ulrich, Berlin, Germany, Federal Republic of
Renneke, Franz-Josef, Bergkamen, Germany, Federal Republic of
Conrad, Juergen, Berlin, Germany, Federal Republic of
Muetzel, Wolfgang, Berlin, Germany, Federal Republic of

PA Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of
(non-U.S. corporation)

PI US 5482700 960109

AI US 94-269504 940701 (8)

RLI Continuation of Ser. No. US 93-66646, filed on 25 May 1993, now
abandoned which is a continuation of Ser. No. US 91-715713, filed
on 18 Jun 1991, now abandoned which is a continuation of Ser. No.
US 89-430442, filed on 2 Oct 1989, now abandoned

PRAI DE 87-3710730 870331

DT Utility

LN.CNT 2755

L16 ANSWER 5 OF 14 USPATFULL

AN 95:98333 USPATFULL

TI Medical scanning and treatment system and method

IN Lemelson, Jerome H., 868 Tyner Way, Incline Village, NV, United
States 89450

PI US 5464013 951107

AI US 91-799428 911125 (7)

RLI Continuation-in-part of Ser. No. US 91-717080, filed on 18 Jun
1991 which is a continuation-in-part of Ser. No. US 87-54277,
filed on 10 Sep 1987, now abandoned which is a
continuation-in-part of Ser. No. US 84-614021, filed on 25 May
1984, now patented, Pat. No. US 4671256 which is a
continuation-in-part of Ser. No. US 84-614038, filed on 25 May
1984, now patented, Pat. No. US 4665897

DT Utility

LN.CNT 1769

L16 ANSWER 6 OF 14 USPATFULL

AN 95:86363 USPATFULL

TI Immunoassay and kit for in vitro detection of soluble DesAABB
fibrin polymers

IN Gargan, Paul E., Southbend, IN, United States
Ploplis, Victoria A., Leuven, Belgium

Pleasants, Julian R., Granger, IN, United States

PA American Biogenetic Sciences, Inc., Copiague, NY, United States
(U.S. corporation)

PI US 5453359 950926

AI US 93-86423 930702 (8)

RLI Continuation-in-part of Ser. No. US 93-81914, filed on 22 Jun
1993, now abandoned which is a continuation of Ser. No. US
92-835800, filed on 14 Feb 1992, now patented, Pat. No. US 5223410
which is a continuation of Ser. No. US 89-364053, filed on 8 Jun
1989, now patented, Pat. No. US 5120834 which is a
continuation-in-part of Ser. No. US 88-206259, filed on 13 Jun
1988, now abandoned

DT Utility

LN.CNT 2550

L16 ANSWER 7 OF 14 USPATFULL

AN 93:91752 USPATFULL

TI Polypeptide linkers for production of biosynthetic proteins

IN Huston, James S., Newton, MA, United States

Oppermann, Hermann, Medway, MA, United States

PA Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S.
corporation)

PI US 5258498 931102

WO 8809344 881201

AI US 92-955399 921001 (7)

WO 88-US1737 880519

890123 PCT 371 date

890123 PCT 102(e) date

RLI Continuation of Ser. No. US 89-342449, filed on 23 Jan 1989, now
abandoned which is a continuation-in-part of Ser. No. US 87-52800,
filed on 21 May 1987, now abandoned

DT Utility

LN.CNT 1671

L16 ANSWER 8 OF 14 USPATFULL

AN 93:52488 USPATFULL

TI Method for production of antibodies utilizing an antigen-free
animal

IN Gargan, Paul E., Southbend, IN, United States

Ploplis, Victoria A., Southbend, IN, United States

Pleasants, Julian R., Granger, IN, United States

PA American Biogenetic Sciences, Inc., Copiague, NY, United States
(U.S. corporation)

PI US 5223410 930629

AI US 92-835800 920214 (7)

RLI Continuation of Ser. No. US 89-364053, filed on 8 Jun 1989, now
patented, Pat. No. US 5120834 which is a continuation-in-part of
Ser. No. US 88-206259, filed on 13 Jun 1988, now abandoned

DT Utility
LN.CNT 1655

L16 ANSWER 9 OF 14 USPATFULL

AN 92:47159 USPATFULL

TI ***Fibrin*** -specific monoclonal antibody

IN Gargan, Paul E., Southbend, IN, United States
Ploplis, Victoria A., Southbend, IN, United States
Pleasants, Julian R., Granger, IN, United States

PA American Biogenetic Sciences, Inc., Copaique, NY, United States
(U.S. corporation)

PI US 5120834 920609

AI US 89-364053 890608 (7)

RLI Continuation-in-part of Ser. No. US 88-206259, filed on 13 Jun
1988

DT Utility

LN.CNT 1713

INCL INCLM: 530/388.250

INCLS: 435/240.270; 435/172.200; 435/070.210; 424/085.800;
424/001.100; 424/009.000; 530/391.300

NCL NCLM: 530/388.250

NCLS: 424/145.100; 424/178.100; 435/070.210; 435/172.200;
435/337.000; 530/391.300

IC [5]

ICM: C07K015-28

ICS: C12N005-12; C12N015-02; A61K039-395

EXF 530/387; 530/388; 530/387; 435/240.26; 435/240.27; 435/172.2;
435/240.27; 935/100; 935/104; 424/85.8; 424/1.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 14 USPATFULL

AN 92:15138 USPATFULL

TI Fibrinogen-specific monoclonal antibody

IN Gargan, Paul E., Southbend, IN, United States
Ploplis, Victoria A., Southbend, IN, United States
Pleasants, Julian R., Granger, IN, United States

PA American Biogenetic Sciences, Inc., Copaique, NY, United States
(U.S. corporation)

PI US 5091512 920225

AI US 90-583738 901010 (7)

RLI Division of Ser. No. US 89-364053, filed on 8 Jun 1989 which is a
continuation-in-part of Ser. No. US 88-206259, filed on 3 Jun 1988

DT Utility
LN.CNT 1633

L16 ANSWER 11 OF 14 USPATFULL

AN 91:98212 USPATFULL

TI Intra-vaginal device and method

IN Cohen, Robert S., New York, NY, United States

Pierce, James M., Coral Gables, FL, United States

Kinsey, William H., Coral Gables, FL, United States

PA MaxiMed Corporation, New York, NY, United States (U.S. corporation)

PI US 5069906 911203

AI US 90-625808 901211 (7)

RLI Continuation of Ser. No. US 88-257156, filed on 14 Oct 1988, now patented, Pat. No. US 4983393 which is a continuation of Ser. No. US 87-57898, filed on 21 Jul 1987, now abandoned

DT Utility

LN.CNT 436

AN 91:2888 USPATFULL

TI Intra-vaginal device and method for sustained drug release

IN Cohen, Robert S., New York, NY, United States

Pierce, James M., Coral Gables, FL, United States

Kinsey, William H., Coral Gables, FL, United States

PA MaxiMed Corporation, New York, NY, United States (U.S. corporation)

PI US 4983393 910108

AI US 88-257156 881014 (7)

RLI Continuation of Ser. No. US 87-75898, filed on 21 Jul 1987, now abandoned

DT Utility

LN.CNT 440

L16 ANSWER 13 OF 14 USPATFULL

AN 89:73977 USPATFULL

TI Methods for circumventing the problem of free radical reduction associated with the use of stable nitroxide free radicals as contrast agents for magnetic resonance imaging

IN Keana, John F. W., Eugene, OR, United States

PA The State of Oregon Acting by and Through the State Board of Higher Education on Behalf of the University of Oregon, Eugene, OR, United States (U.S. corporation)

PI US 4863717 890905

AI US 86-928943 861110 (6)

DT Utility

LN.CNT 927

L16 ANSWER 14 OF 14 USPATFULL

AN 88:27604 USPATFULL

TI Antibody-metal ion complexes

IN Alvarez, Vernon L., Morrisville, PA, United States

Rodwell, John D., Yardley, PA, United States

Lee, Chyi, New Brunswick, NJ, United States

Goers, John W. F., Atascadero, CA, United States

Siegel, Richard C., Yorktown Heights, NY, United States

McKearn, Thomas J., New Hope, PA, United States

PA Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)

PI US 4741900 880503

AI US 84-646328 840831 (6)

RLI Continuation-in-part of Ser. No. US 82-442050, filed on 16 Nov 1982, now abandoned which is a continuation-in-part of Ser. No. US 82-356315, filed on 9 Mar 1982, now patented, Pat. No. US 4671958

DT Utility

LN.CNT 1687

=> s drug(5w)deliv? and fibrin(20a)(antibod? or immunoglo?)

L17 23 DRUG(5W)DELIV? AND FIBRIN(20A)(ANTIBOD? OR IMMUNOGLO?)

=> s l17 not l16

L18 15 L17 NOT L16

=> d 1-15

L18 ANSWER 1 OF 15 USPATFULL

AN 97:86587 USPATFULL

TI .alpha.-ketoamide derivatives as inhibitors of thrombosis

IN Abelman, Matthew M., Solana Beach, CA, United States

Pearson, Daniel A., Bedford, NH, United States

Vlasuk, George P., Carlsbad, CA, United States

Webb, Thomas R., Encinitas, CA, United States

PA Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

PI US 5670479 970923

AI US 94-218329 940325 (8)

RLI Continuation-in-part of Ser. No. US 93-37574, filed on 25 Mar 1993

DT Utility

LN.CNT 4649

L18 ANSWER 2 OF 15 USPATFULL

AN 97:83597 USPATFULL

TI Compounds, compositions and methods for binding bio-affecting

substances to surface membranes of bio-particles

IN Kopia, Gregory A., Phoenixville, PA, United States
Horan, Paul K., Downingtown, PA, United States
Gray, Brian D., Ardmore, PA, United States
Troutner, David E., Phoenixville, PA, United States
Muirhead, Katharine A., West Chester, PA, United States
Sheth, Kamleshkumar A., Downingtown, PA, United States
Lin, Chia-En, Norristown, PA, United States
Yu, Zhizhou, Jeffersonville, PA, United States
Jensen, Bruce D., Collegeville, PA, United States
Slezak, Sue Ellen, Downingtown, PA, United States

PA Zynaxis, Inc., Malvern, PA, United States (U.S. corporation)

PI US 5667764 970916

AI US 92-884432 920515 (7)

RLI Continuation-in-part of Ser. No. US 88-189192, filed on 2 May
1988, now abandoned

DT Utility

LN.CNT 3547

L18 ANSWER 3 OF 15 USPATFULL

AN 97:71036 USPATFULL

TI .alpha.-ketoamide derivatives as inhibitors of thrombosis

IN Abelman, Matthew M., Solana Beach, CA, United States
Pearson, Daniel A., Solana Beach, CA, United States
Vlasuk, George P., Carlsbad, CA, United States
Webb, Thomas R., Encinitas, CA, United States

PA Corvas International, Inc., San Diego, CA, United States (U.S.
corporation)

PI US 5656600 970812

AI US 93-37574 930325 (8)

DT Utility

LN.CNT 4360

L18 ANSWER 4 OF 15 USPATFULL

AN 97:64046 USPATFULL

TI Nitric oxide-releasing polymers to treat restenosis and related
disorders

IN Keefer, Larry K., Bethesda, MD, United States
Hutsell, Thomas C., North Oaks, MN, United States

PA The United States of America as represented by the Secretary of
the Department of Health and Human Services, Washington, DC,
United States (U.S. government)

Comedicus, Incorporated, Long Lake, MN, United States (U.S.
corporation)

PI US 5650447 970722

AI US 94-214372 940317 (8)

RLI Continuation-in-part of Ser. No. US 93-121169, filed on 14 Sep 1993, now patented, Pat. No. US 5525357 which is a continuation-in-part of Ser. No. US 92-935565, filed on 24 Aug 1992, now patented, Pat. No. US 5405919

DT Utility

LN.CNT 1417

L18 ANSWER 5 OF 15 USPATFULL

AN 97:44760 USPATFULL

TI Antibodies specific for E-selectin and the uses thereof

IN Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States

PA Brigham & Women's Hospital, Boston, MA, United States (U.S. corporation)

PI US 5632991 970527

AI US 94-365470 941229 (8)

RLI Continuation-in-part of Ser. No. US 93-102510, filed on 5 Aug 1993, now patented, Pat. No. US 5403713 which is a continuation of Ser. No. US 92-850802, filed on 13 Mar 1992, now abandoned which is a division of Ser. No. US 88-270860, filed on 14 Nov 1988, now abandoned

DT Utility

LN.CNT 2191

L18 ANSWER 6 OF 15 USPATFULL

AN 97:31410 USPATFULL

TI Methods of inhibiting the activation of Factor XIII

IN Reed, Guy L., Winchester, MA, United States

Matsueda, Gary R., Princeton, NJ, United States

Haber, Edgar, Salisbury, NH, United States

PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

General Hospital Corporation, The, Boston, MA, United States (U.S. corporation)

PI US 5620688 970415

WO 9215609 920917

AI US 94-117052 940504 (8)

WO 92-US1926 920311

940504 PCT 371 date

940504 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 91-667296, filed on 11 Mar 1991, now abandoned

DT Utility

L18 ANSWER 7 OF 15 USPATFULL

AN 97:22504 USPATFULL

TI Acoustically reflective liposomes and methods to make and use same

IN Lanza, Gregory M., Evanston, IL, United States

Onyuksel, M. Hayat, LaGrange, IL, United States

Klegerman, Melvin E., Chicago, IL, United States

Vonesh, Michael J., Northbrook, IL, United States

McPherson, David L., Chicago, IL, United States

PA Northwestern University, Evanston, IL, United States (U.S. corporation)

PI US 5612057 970318

AI US 95-541185 951011 (8)

RLI Continuation of Ser. No. US 94-329145, filed on 12 Oct 1994, now abandoned which is a continuation of Ser. No. US 92-865480, filed on 9 Apr 1992, now abandoned

DT Utility

LN.CNT 900

L18 ANSWER 8 OF 15 USPATFULL

AN 96:120572 USPATFULL

TI Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease

IN Anderson, Stephen, Princeton, NJ, United States

PA Rutgers, The State University of New Jersey, Piscataway, NJ, United States (U.S. corporation)

PI US 5589154 961231

AI US 94-347144 941122 (8)

DT Utility

LN.CNT 1362

L18 ANSWER 9 OF 15 USPATFULL

AN 96:113668 USPATFULL

TI ***Antibodies*** that bind to .alpha.2-antiplasmin crosslinked to ***fibrin*** which do not inhibit plasma .alpha.2-antiplasmin

IN Reed, Guy L., Winchester, MA, United States

Haber, Edgar, Salisbury, NH, United States

Matsueda, Gary R., Princeton, NJ, United States

PA General Hospital Corporation, Boston, MA, United States (U.S. corporation)

PI US 5582862 961210

AI US 92-980520 921201 (7)

RLI Continuation-in-part of Ser. No. US 92-943372, filed on 10 Sep 1992, now patented, Pat. No. US 5372812, issued on 13 Dec 1994 which is a continuation of Ser. No. US 90-589003, filed on 27 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. US

88-177222, filed on 4 Apr 1988, now abandoned

DT Utility

LN.CNT 913

INCL INCLM: 424/145.100

INCLS: 424/141.100; 424/094.630; 424/094.640; 530/388.250;
530/382.260

NCL NCLM: 424/145.100

NCLS: 424/094.630; 424/094.640; 424/141.100; 530/388.250;
530/388.260

IC [6]

ICM: A61K039-395

ICS: A61K038-48

EXF 424/85.8; 424/94.63; 424/94.64; 424/141.1; 424/145.1; 530/388.25;
530/388.26

L18 ANSWER 10 OF 15 USPATFULL

AN 96:3719 USPATFULL

TI Complexes of nitric oxide with cardiovascular amines as dual
acting cardiovascular agents

IN Hutsell, Thomas C., North Oaks, MN, United States

PA Comedicus Incorporated, Long Lake, MN, United States (U.S.
corporation)

PI US 5482925 960109

AI US 94-210043 940317 (8)

DT Utility

LN.CNT 646

L18 ANSWER 11 OF 15 USPATFULL

AN 95:90090 USPATFULL

TI Drugs and methods for treating diseases

IN Lemelson, Jerome H., 868 Tyner Way, Incline Village, NV, United
States 89450

PI US 5456663 951010

AI US 91-717080 910618 (7)

RLI Continuation-in-part of Ser. No. US 87-54227, filed on 10 Sep
1987, now abandoned which is a continuation-in-part of Ser. No. US
84-614021, filed on 25 May 1984, now patented, Pat. No. US 4671256
which is a continuation-in-part of Ser. No. US 84-614038, filed on
25 May 1984, now patented, Pat. No. US 4665897

DT Utility

LN.CNT 1376

L18 ANSWER 12 OF 15 USPATFULL

AN 94:108736 USPATFULL

TI Composition and method for acceleration of clot lysis

IN Reed, Guy L., Cambridge, MA, United States
Matsueda, Gary R., Princeton, NJ, United States
Haber, Edgar, New York, NY, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S.
corporation)
PI US 5372812 941213
AI US 92-943372 920910 (7)
RLI Continuation of Ser. No. US 90-589003, filed on 27 Sep 1990, now
abandoned which is a continuation-in-part of Ser. No. US
88-177222, filed on 4 Apr 1988, now abandoned
DT Utility
LN.CNT 1567

L18 ANSWER 13 OF 15 USPATFULL

AN 94:40061 USPATFULL
TI Uses for thioureylenes
IN Elias, Alan N., 2984 Alpine Way, Laguna Beach, CA, United States
92651
PI US 5310742 940510
AI US 92-982702 921130 (7)
DT Utility
LN.CNT 1308

L18 ANSWER 14 OF 15 USPATFULL

AN 94:1207 USPATFULL
TI Method of treatment for myocardial infarction
IN Gold, Herman K., Boston, MA, United States
Coller, Barry S., Dix Hills, NY, United States
Collen, Desire, Winksele-Herent, Belgium
PA The General Hospital Corporation, Boston, MA, United States (U.S.
corporation)
The Research Foundation of State University of New York, Stony
Brook, NY, United States (U.S. corporation)
PI US 5275812 940104
AI US 93-22838 930225 (8)
RLI Continuation of Ser. No. US 91-764088, filed on 23 Sep 1991, now
abandoned which is a continuation of Ser. No. US 88-206900, filed
on 14 Jun 1988, now abandoned which is a continuation-in-part of
Ser. No. US 87-35328, filed on 7 Apr 1987, now abandoned which is
a continuation-in-part of Ser. No. US 85-742208, filed on 7 Jun
1985, now abandoned Ser. No. Ser. No. US 85-742187, filed on 7 Jun
1985, now abandoned And Ser. No. US 86-851711, filed on 14 Apr
1986, now abandoned which is a continuation-in-part of Ser. No. US
85-745415, filed on 14 Jun 1985, now abandoned
DT Utility

LN.CNT 1036

L18 ANSWER 15 OF 15 USPATFULL

AN 91:40366 USPATFULL

TI Drug units and methods for treating blood clots

IN Lemelson, Jerome H., 48 Parkside Dr., Princeton, NJ, United States
08540

PI US 5017379 910521

AI US 88-228011 880804 (7)

RLI Continuation-in-part of Ser. No. US 85-809207, filed on 16 Dec
1985, now patented, Pat. No. US 4764359 And a continuation-in-part
of Ser. No. US 84-631605, filed on 17 Jul 1984, now patented, Pat.

No. US 4674480 And a continuation-in-part of Ser. No. US

84-614038, filed on 25 May 1984, now patented, Pat. No. US 4665897

And a continuation-in-part of Ser. No. US 84-614021, filed on 25

May 1984, now patented, Pat. No. US 4671256

DT Utility

LN.CNT 1011

=> file home

=> index bioscience

=> s fibrin(20a)(antibod? or immunoglo?) and delivery

1 FILE BIOBUSINESS

8 FILE BIOSIS

10 FILES SEARCHED...

9 FILE CAPLUS

4 FILE CJACS

0* FILE DDFU

21 FILES SEARCHED...

39 FILE DRUGU

5 FILE EMBASE

2 FILE IFIPAT

2 FILE LIFESCI

4 FILE MEDLINE

37 FILES SEARCHED...

1 FILE PHIN

3 FILE PROMT

4 FILE SCISEARCH

1 FILE TOXLIT

76 FILE USPATFULL

2 FILE WPIDS

Connection closed by remote host

<-----User Break----->

L27 ANSWER 1 of 5 COPYRIGHT 1997 ACS
 AN 95:5608 CJACS
 SO Journal of Pharmaceutical Sciences, (1995), 84(4), 399-403. CODEN: JPMSAE. ISSN: 0022-3549
 TI Preparation and Characterization of Fibrinogen-Coated, Reversibly Adhesive, Lecithin/Cholesterol Vesicles
 AU (1) DeAnglis, Ashley P.; (2) Retzinger, Gregory S.
 CS (1,2) Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267

L27 ANSWER 2 OF 5 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
 AN 94-50254 DRUGU P G
 TI ~~Local drug delivery for the prevention of restenosis: fact, fancy,~~
 and future.
 AU Lincoff A M; Topol E J; Ellis S G
 CS Cleveland-Clinic-Found.
 LO Cleveland, Ohio, United States
 SO Circulation (90, No. 4, 2070-84, 1994) 5 Fig. 122 Ref.
 CODEN: CIRCAZ ISSN: 0009-7322
 AV No Reprint Address
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature

L27 ANSWER 3 OF 5 DRUGU COPYRIGHT 1997 DERWENT INFORMATION LTD
 AN 88-10117 DRUGU T S
 TI Immobilized Thrombolytic Enzymes for Systemic and Local Application.
 AU Torchilin V P; Maksimenko A V; Mazaev A V
 LO Moscow, Russia
 SO Ann.N.Y.Acad.Sci. (501, 481-86, 1987) 15 Ref.
 CODEN: ANYAA9 ISSN: 0077-8923
 AV USSR Cardiology Research Center, Moscow 121552, U.S.S.R.
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature

L27 ANSWER 4 OF 5 IFIPAT COPYRIGHT 1997 IFI
 AN 2820330 IFIPAT;IFIUDB;IFICDB
 TI COATED IMPLANTABLE MEDICAL DEVICE
 IN Fearnot Neal E; Kozma Thomas G; Ragheb Anthony O; Voorhees William D
 PA MED Institute Inc (35197)
 PI US 5609629 970311
 AI US 95-484532 950607
 FI US 5609629 970311
 DT UTILITY
 FS CHEMICAL MECHANICAL
 CHEMICAL
 MECHANICAL
 CLMN 19
 GI 2 Drawing Sheet; 5 Figures;

L27 ANSWER 5 OF 5 IFIPAT COPYRIGHT 1997 IFI
AN 2733059 IFIPAT;IFIUDB;IFICDB
TI METHODS AND COMPOSITIONS FOR THE DIRECT CONCENTRATED DELIVERY OF
PASSIVE IMMUNITY; INSERTABLE DEVICE COATED WITH
IMMUNOGLOBULINS TO PREVENT INFECTION AT SURGICAL OR TRAUMA
SITES; CONTACT LENSES, -CATHETERS, -VASCULAR GRAFTS
IN Gristina Anthony G; Myrvik Quentin N
PA Unassigned Or Assigned To Individual (68000)
PI US 5530102 960625
AI US 95-441299 950515
RLI US 93-3305 930112 CONTINUATION ABANDONED
US 94-295482 940825 DIVISION
FI US 5530102 960625
DT UTILITY
FS CHEMICAL
CLMN 7
